Head-to-head · WeighScore
Genesis Lifestyle Medicine vs NuuVim
The verdict
NuuVim takes it — 68.2/100 to 57.7/100.
NuuVim grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. NuuVim is a Texas-based DTC telehealth program offering compounded semaglutide and tirzepatide in both injectable and oral forms — oral access is uncommon here — plus limited brand-name Ozempic and Zepbound.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Genesis Lifestyle Medicine | NuuVim |
|---|---|---|
| WeighScore | 57.7/100 | 68.2/100 |
| Grade | C | C |
| Scorecard rank | #392 | #153 |
| Semaglutide | Not disclosed | $79/mo (all doses, 3-mo plan, new patients only, compounded) |
| Tirzepatide | Not disclosed | $133/mo (all doses, 3-mo plan, new patients only, compounded) |
| Coverage | 8 states | Coverage not published |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Injection only | Yes |
Graded #392 · C
Strengths
- 18 physical clinics allow in-person consults and injections across 8 states
- Dual modality — compounded sema/tirz plus brand-name Wegovy and Zepbound on one platform
- Med spa model lets patients combine weight loss, hormone therapy, and aesthetics
- Established brand with an 18-location footprint and patient testimonials
- Telehealth available for remote patients in served states
Where it loses points
- Pricing not disclosed publicly — gated behind the consultation flow
- Specific 503A/503B pharmacy partner not named, and the designation not specified
- No FDA compounded-medication disclaimer visible on the homepage
- Named medical director not formally disclosed (only a 'Dr. Spinoso' testimonial)
- Corporate legal entity and governing law not disclosed
Graded #153 · C
Strengths
- Low compounded entry pricing — semaglutide from $79/mo, tirzepatide from $133/mo, flat all-dose pricing
- Both injectable and oral compounded options for semaglutide and tirzepatide (oral access is uncommon)
- LegitScript Certified and HIPAA-compliant
- Two named compounding pharmacy partners (Hallandale Pharmacy and Pharmacy Hub), both vetted in our directory
- Operating legal entity disclosed: NuuVim LLC, Texas governing law
Where it loses points
- There is no month-to-month plan: every rate is billed as one three-month payment
- The advertised $79 and $133 are introductory rates for customers new to GLP-1s; on renewal they become $133 and $199.67
- The site's own llms.txt advertises pricing, FAQ and terms files that all 404
- No state count is published
- FDA issued this company a warning letter dated 19 March 2025; the letter is public in FDA's warning-letter database
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.